www.88sbc.com_www.88sbc.com-【分出胜负】

社友网

2019-11-13 23:42:53

字体:标准

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:

  MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesareneededtodemonstratethatthemedicinemeetsthestandardsforsafetyandefficacythatgovernmentregulatoryagencieshaveestablishedforgrantingapproval.Gainingregulatoryapprovalforamedicineisthebestwaytobringrapidaccesstothegreatestnumberofpatientswhomaybenefit.Forpatientswithaseriousorlife-threateningdiseasewhoareineligibleorunabletoparticipateinaclinicaltrial,useofanexpandedaccessprogrammaybeanoption.Dependingoncountryregulationsandtheprogramcriteria,accesstoinvestigationalmedicinesmaybeprovidedthroughExpandedAccessPrograms(EAP)(knownascompassionateuseprogramsincertainjurisdictions),orCountry-SpecificAuthorizationtoUsecohorts.DecisionCriteriaforConsideringanEAPThefollowingcriteriamustbemetbeforeMSDwillconsiderestablishinganEAPforaMSDinvestigationalproduct:MSD.com | About | Views & Positions | Access to Investigational Medicines#标题分割#ExpandingPatientAccesstoMSD'sInvestigationalMedicinesWhenresultsfromclinicaltrialssuggestthatoneofourinvestigationalmedicinesmayofferbenefitsforpatientsfacinglife-threateningconditions,MSDiscommittedtobringingthatmedicinetothosepatientsasquicklyandequitablyaspossible.Participationinclinicaltrialsshouldbetheprimaryroutebywhichpatientsgetaccesstoinvestigationalmedicinesandcontributetothecollectionofsafetyandefficacydataneededtosupportregulatoryapprovalworldwide.Theseclinicalstudiesaren